siRNA Therapeutics in Ocular Diseases
The field of RNAi therapeutics has quickly adapted to the treatment of ocular diseases. Although the eye provides a unique system for the delivery of siRNAs, its complex structure and composition fostered the development of novel strategies for efficient gene silencing in the target compartment. Mor...
Saved in:
Published in | Methods in molecular biology (Clifton, N.J.) Vol. 2282; p. 417 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.01.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The field of RNAi therapeutics has quickly adapted to the treatment of ocular diseases. Although the eye provides a unique system for the delivery of siRNAs, its complex structure and composition fostered the development of novel strategies for efficient gene silencing in the target compartment. Moreover, anterior and posterior segments differ in their multiple drug barriers and clearance mechanisms. This chapter summarizes the recent achievements in terms of routes of administration, chemical modifications, and delivery systems for siRNAs that specifically apply to eye disorders. Methods employed for siRNA detection/quantitation in ocular tissues are also described, together with safety concerns that need to be addressed to fulfill regulatory requirements of new drug approval. Even though RNAi therapies for ocular diseases have not yet translated into patient care, we document herein the rising number of candidate drugs currently under preclinical or clinical development. |
---|---|
AbstractList | The field of RNAi therapeutics has quickly adapted to the treatment of ocular diseases. Although the eye provides a unique system for the delivery of siRNAs, its complex structure and composition fostered the development of novel strategies for efficient gene silencing in the target compartment. Moreover, anterior and posterior segments differ in their multiple drug barriers and clearance mechanisms. This chapter summarizes the recent achievements in terms of routes of administration, chemical modifications, and delivery systems for siRNAs that specifically apply to eye disorders. Methods employed for siRNA detection/quantitation in ocular tissues are also described, together with safety concerns that need to be addressed to fulfill regulatory requirements of new drug approval. Even though RNAi therapies for ocular diseases have not yet translated into patient care, we document herein the rising number of candidate drugs currently under preclinical or clinical development. |
Author | González, María Victoria Martínez, Tamara Bleau, Anne-Marie Moreno-Montañés, Javier Jiménez, Ana Isabel Vargas, Beatriz |
Author_xml | – sequence: 1 givenname: Javier surname: Moreno-Montañés fullname: Moreno-Montañés, Javier email: jmoreno@unav.es organization: Clínica Universidad de Navarra, Pamplona, Spain. jmoreno@unav.es – sequence: 2 givenname: Anne-Marie surname: Bleau fullname: Bleau, Anne-Marie organization: Sylentis, Madrid, Spain – sequence: 3 givenname: Tamara surname: Martínez fullname: Martínez, Tamara organization: Sylentis, Madrid, Spain – sequence: 4 givenname: Beatriz surname: Vargas fullname: Vargas, Beatriz organization: Sylentis, Madrid, Spain – sequence: 5 givenname: María Victoria surname: González fullname: González, María Victoria organization: Sylentis, Madrid, Spain – sequence: 6 givenname: Ana Isabel surname: Jiménez fullname: Jiménez, Ana Isabel organization: Sylentis, Madrid, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33928588$$D View this record in MEDLINE/PubMed |
BookMark | eNo1jstKA0EQAAdRzEP_QGQvHkd7uud5DDE-IBiQeF4ms704kqzLTvbg3yuopzoUFDUTp91nx0JcKbhVAO4uOC-VBKesVBi8DDXSiZiqoEFawDARs1I-ALQj1OdiQhTQG--n4qbk15dFtX3nIfY8HnMqVe6qTRr3cajuc-FYuFyIszbuC1_-cS7eHlbb5ZNcbx6fl4u1TKTxKL2BdkcIibnRymtrlPMWvYXomDi0wK1zP8qlZCgQaIyGQTeNBmQyOBfXv91-3B24qfshH-LwVf__4jeni0B7 |
CitedBy_id | crossref_primary_10_1016_j_jep_2023_116993 crossref_primary_10_1039_D2OB02099H crossref_primary_10_1016_j_prp_2024_155328 crossref_primary_10_1016_j_jddst_2024_105847 crossref_primary_10_1021_acsomega_3c01703 crossref_primary_10_1016_j_addr_2023_115073 |
ContentType | Journal Article |
DBID | NPM |
DOI | 10.1007/978-1-0716-1298-9_23 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1940-6029 |
ExternalDocumentID | 33928588 |
Genre | Journal Article |
GroupedDBID | --- 29M 53G ACGFS ALMA_UNASSIGNED_HOLDINGS F5P NPM P2P RSU SPO UDS WH7 ZGI |
ID | FETCH-LOGICAL-c342t-850fb320ceed41846517862860a7e3e9f0ef77d417cc5393042a5e04dd402e352 |
IngestDate | Thu May 23 23:39:04 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Keywords | Eye delivery systems Biodistribution Ocular diseases siRNA modifications |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c342t-850fb320ceed41846517862860a7e3e9f0ef77d417cc5393042a5e04dd402e352 |
PMID | 33928588 |
ParticipantIDs | pubmed_primary_33928588 |
PublicationCentury | 2000 |
PublicationDate | 2021-01-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Methods in molecular biology (Clifton, N.J.) |
PublicationTitleAlternate | Methods Mol Biol |
PublicationYear | 2021 |
SSID | ssj0047324 |
Score | 2.4107199 |
SecondaryResourceType | review_article |
Snippet | The field of RNAi therapeutics has quickly adapted to the treatment of ocular diseases. Although the eye provides a unique system for the delivery of siRNAs,... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 417 |
Title | siRNA Therapeutics in Ocular Diseases |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33928588 |
Volume | 2282 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcK0yZepo1twBgoD_A0GTmJ0ziPlA8hpBYJFcRb5ThnCYmmVQkPq_bHc_YlbcTHNHiJojix4tzlfHe-n3-M7YEwoc1Bcw1ZwWWoLM-1krwLViYKlDbgq3wH3bMreX6T3HQ6f9vokio_MPMXcSXvkSpeQ7k6lOwbJLvoFC_gOcoXjyhhPP6XjO9vLwe-aKKBUPni1gsqLT2mpZf7tvvZ93zR_q5xw4v7u9mHidZzbdVAsM4PWmmC_mQG5YSjCUB38yje74W0xE5qoN3suojs70A_ULFkCbzvgvFl3ntW-eeOS8pcD_VYzxYzw7Vj3fU99sBRB8zbOYkobOUkgOxo5lAFon7L2tBGEfEM1bZSEmjzmQ1flm2EDl7laIIyNMojwiW3xDode7nG6OKphMgB_936ZGftpmmFraTKWceBy_TQLC5T9DRbUMuXXmeNfWq6eBKUeOdk-IV9rqOK4JBU5CvrQLnOPhLP6J9vbN8rStBWlOC2DEhRgkZRvrOr05Ph0Rmv-TG4iWVUcZUIm8eRcH4O_mWO1R7HEamu0CnEkFkBNk2xKTUmiTOXuNIJCFkUUkSAnvcPtlpOSthkgcEo07hYV8SFNKKbmUhpW2iMzpWNE9hiGzS-0ZQ2QRk1I__5ass2W1vqxi_2weJfBzvowlX5rv_Wj1TGPaY |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=siRNA+Therapeutics+in+Ocular+Diseases&rft.jtitle=Methods+in+molecular+biology+%28Clifton%2C+N.J.%29&rft.au=Moreno-Monta%C3%B1%C3%A9s%2C+Javier&rft.au=Bleau%2C+Anne-Marie&rft.au=Mart%C3%ADnez%2C+Tamara&rft.au=Vargas%2C+Beatriz&rft.date=2021-01-01&rft.eissn=1940-6029&rft.volume=2282&rft.spage=417&rft_id=info:doi/10.1007%2F978-1-0716-1298-9_23&rft_id=info%3Apmid%2F33928588&rft_id=info%3Apmid%2F33928588&rft.externalDocID=33928588 |